HUTCHMED (China) Limited ADR (HCM)

HUTCHMED (China) Limited ADR Borsa (HCM) Ultime notizie

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board ... - Yahoo Finance UK

Yahoo Finance UK

HUTCHMED (LON:HCM) Stock Crosses Above 200-Day Moving Average of $271.21 - Defense World

Defense World

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

GlobeNewswire Inc.

TCOM: 3 China Stocks to Watch in May - StockNews.com

StockNews.com

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

GlobeNewswire Inc.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire Inc.

HUTCHMED (LON:HCM) Shares Pass Above 200-Day Moving Average of $268.65 - Defense World

Defense World

HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? - Zacks Investment Research

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? - Zacks Investment Research

Zacks Investment Research

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

GlobeNewswire Inc.

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

GlobeNewswire Inc.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

GlobeNewswire Inc.

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

GlobeNewswire Inc.

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

GlobeNewswire Inc.

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

Benzinga

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

GlobeNewswire Inc.

Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

Zacks Investment Research

Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

GlobeNewswire Inc.

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

GlobeNewswire Inc.

HUTCHMED to Announce 2023 Final Results

GlobeNewswire Inc.

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

GlobeNewswire Inc.

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

GlobeNewswire Inc.

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

GlobeNewswire Inc.

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

GlobeNewswire Inc.

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

GlobeNewswire Inc.

Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

Benzinga

When companies leave AIM for Nasdaq: is the grass greener? - Interactive Investor

Interactive Investor

Nio, Xpeng and 86 others added to SEC's list of firms facing possible delisting - CnEVPost

CnEVPost

What Happens to Your ETFs if Chinese ADRs Delist? - Morningstar HK

Morningstar HK

Are Delistings of Chinese Stocks on Their Way? - Morningstar

Morningstar

HCM HUTCHMED (China) Limited - Quantisnow

Quantisnow

Trinity Delta Equity Research & Stock Reports - Research Tree

Research Tree

HUTCHMED (HCM) Stock Price, News & Analysis - MarketBeat

MarketBeat